JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265415

Human EXOC7 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

EXOC7 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 245 bp insertion in exon 3 and Insertion of the selection cassette in exon 3.

View Alternative Names

2 5 3p, DKFZp686J04253, EX070, EXO70, EXOC7_HUMAN, Exo70p, Exocyst complex component 7, Exocyst complex component Exo70, FLJ40965, FLJ46415, KIAA1067, Rexo70, YJL085W

2 Images
Sanger Sequencing - Human EXOC7 knockout HeLa cell line (AB265415)
  • Sanger seq

Unknown

Sanger Sequencing - Human EXOC7 knockout HeLa cell line (AB265415)

Allele-1 : 245 bp insertion in exon 3.

Sanger Sequencing - Human EXOC7 knockout HeLa cell line (AB265415)
  • Sanger seq

Unknown

Sanger Sequencing - Human EXOC7 knockout HeLa cell line (AB265415)

Allele-2 : Insertion of the selection cassette in exon 3.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 245 bp insertion in exon 3 and Insertion of the selection cassette in exon 3

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265415-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265415 Human EXOC7 knockout HeLa cell line", "number":"AB265415-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265415-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265415 Human EXOC7 knockout HeLa cell line", "number":"AB265415-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
EXOC7
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

EXOC7 also known as Exocyst Complex Component 7 is a part of the exocyst complex involved in the regulation of vesicle trafficking. This protein weighs approximately 76 kDa and functions by facilitating the fusion of vesicles with the plasma membrane. It is generally expressed in various tissue types but shows higher levels in lung and brain tissues. EXOC7 often works with other components of the exocyst complex to carry out its role in cellular trafficking.
Biological function summary

EXOC7 plays a significant role in exocyst-mediated processes acting as a critical component of the exocyst complex. This multi-protein complex is essential for targeting secretory vesicles to specific docking sites in the plasma membrane. EXOC7 is involved in processes like cell polarity migration and even in the maintenance of tight junctions. Through its interactions with other exocyst components it aids in the spatial organization of the cell influencing overall cellular architecture and functionality.

Pathways

EXOC7 integrates into exocytosis and cell signaling pathways. It particularly plays a role in the exocytosis pathway which is essential for secretion and cell-surface receptor recycling. EXOC7 interacts with other exocyst complex proteins such as SEC10 and SEC15 promoting efficient vesicle tethering and fusion events. Additionally it links to the ARF6-dependent pathways that affect actin cytoskeleton remodeling demonstrating its importance in cell movement and structural remodeling.

EXOC7's proper function is essential for normal cellular processes and its dysregulation has connections to type 2 diabetes and certain cancers. In type 2 diabetes misregulated exocyst complex activities including those involving EXOC7 can disrupt insulin secretion. In cancer altered expression or function of the exocyst complex may contribute to metastasis due to its role in cell adhesion and migration. EXOC7's interaction with other proteins such as EXOC3L1 and EXOC5 could play a significant role in these disease mechanisms highlighting its potential as a target for therapeutic intervention.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com